NEW YORK--(BUSINESS WIRE)--Genomic Expression, Inc., a leader in the development of innovative sequencing technology for personalized medicine, today announced the successful closing of financing from the Seattle Women’s Impact Fund and the appointment of its co-founder, Kim Tennican, to Genomic Expression’s board of directors.
Ms.Tennican commented, “We are thrilled to be supporting Genomic Expression as they pursue their mission to save lives and make health care more effective. Their genomic-based diagnostics mark a critical step forward in taking the guesswork out of cancer treatments. With Gitte Pedersen’s leadership, Genomic Expression has the opportunity to change the future of cancer treatment in the US, Denmark and beyond.”
Seattle Women’s Impact Fund (SWIF) is an investment group based in Seattle, Washington. SWIF is dedicated to supporting women-founded social impact companies by providing capital as well as expertise from their seasoned members.
SWIF was founded by the inaugural Seattle cohort of Pipeline Fellowship that Gitte Pedersen presented for. Pipeline Fellowship is an investing bootcamp for women whose mission is to change the face of investing by increasing diversity while creating capital for women social entrepreneurs.
Kim Tennican has over 25 years’ experience advising small to mid-sized businesses during all phases from start-up through acquisition as a Principal with Berntson Porter & Company PLLC, a leading tax, accounting and business advisory firm in the Seattle area.
Gitte Pedersen, CEO of Genomic Expression, states “We welcome Kim Tennican to our board where her international tax expertise is truly appreciated as we are now entering a phase where we are selling products and managing revenue streams.”
About Genomic Expression
Genomic Expression’s mission is to save lives and to make the delivery of healthcare more effective. The inconvenient truth is that only one out of four cancer treatments prolong life. Genomic Expression aims to change this by helping doctors select the best drug for their patients, by leveraging it’s clinically focused RNA sequencing technology called OneRNA™.
OneRNA™ can uniquely identify and quantify more than 34,000 RNA’s in one assay and is currently undergoing beta testing by pharma companies and clinicians. Preliminary data suggests that the OneRNA™ assay may be suitable for determining response to the novel immune therapies including the PD1 checkpoint inhibitors.
Genomic Expression will leverage the OneRNA™ assay along with access to clinical samples in a novel partnership model, that enables Genomic Expression to create a pipeline of Next Generation Diagnostics with limited cash burn and minimal regulatory or payer risk, and yet maintain significant product upside.